---
title: "The FDA warns that Novo Nordisk has not reported side effects or death cases related to the weight loss drug Ozempic"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278580386.md"
description: "Novo Nordisk AS received a warning letter from the FDA for failing to report all suspected side effects of the weight loss drug Ozempic. The letter mentioned two cases of death and one case of suicide, with patients all receiving treatment with semaglutide. The FDA did not explicitly state whether these events were related to the drug. The stock recently fell by 3%"
datetime: "2026-03-10T14:45:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278580386.md)
  - [en](https://longbridge.com/en/news/278580386.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278580386.md)
---

# The FDA warns that Novo Nordisk has not reported side effects or death cases related to the weight loss drug Ozempic

Novo Nordisk AS (NVO.US) received a warning letter from the U.S. Food and Drug Administration (FDA) for failing to report all suspected side effects experienced by patients taking its blockbuster weight loss drug Ozempic. The stock price has recently dropped by 3%.

The FDA's letter indicated that the cases included two deaths and one suicide, with patients having received treatment with semaglutide, the generic name for Ozempic and Wegovy. The FDA did not explicitly state whether these deaths or other side effects were related to the drug

### Related Stocks

- [600110.CN](https://longbridge.com/en/quote/600110.CN.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada](https://longbridge.com/en/news/286343869.md)
- [Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial](https://longbridge.com/en/news/286239982.md)
- [Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors](https://longbridge.com/en/news/286980981.md)
- [CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs](https://longbridge.com/en/news/286925029.md)
- [Novo’s CEO champions “record-breaking start” for Wegovy pill in US market](https://longbridge.com/en/news/285719519.md)